an0025
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2020 (NCT04432857)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Prostanoid EP4 receptorINHIBITOR
PTGER4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05358691 | Phase 1 | Jan 30, 2023 | Adlai Nortye Biopharma Co., Ltd., Rutgers University |
| NCT05191667 | Phase 1 | Jan 18, 2022 | Adlai Nortye Biopharma Co., Ltd., People's Liberation Army of China |
| NCT04975958 | Phase 1 | Sep 7, 2021 | Adlai Nortye Biopharma Co., Ltd. |
| NCT04432857 | Phase 1 | Jun 30, 2020 | Adlai Nortye Biopharma Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adlai Nortye Biopharma Co., Ltd. | For profit | 4 | 3 | 1 | 2020 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2022 |
| Rutgers University | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1